Trial Profile
A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy in Patients With Renal Cell Carcinoma at High Risk of Developing Metastasis Following Nephrectomy
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 25 Sep 2023
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary)
- Indications Cancer metastases; Renal cell carcinoma
- Focus Registrational; Therapeutic Use
- Acronyms IMmotion010
- Sponsors Chugai Pharmaceutical; Roche
- 08 Sep 2023 The trial has been completed in Netherlands, Germany, Denmark, Belgium, Poland, France and Spain according to European Clinical Trials Database record.
- 29 Aug 2023 The trial has been completed in Austria (End Date: 08 Dec 2022), according to European Clinical Trials Database record.
- 14 Jul 2023 Status changed from completed to discontinued. The sponsor decided to terminate this study before the protocol-defined end-of-study, as permitted per protocol.